Izalontamab is a bispecific IgG antibody that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It demonstrates significant anti-tumor efficacy and acceptable tolerance in xenograft models of colon cancer, head and neck cancer, and esophageal cancer. MW: 197.22 KD.

Kn026 is a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2), binding to HER2 domains II and IV. It demonstrates a well-tolerated safety profile and promising anti-tumor efficacy in advanced HER2-positive gastric cancer (GC) and gastroesophageal junction cancer (GEJC). MW: 145.19 KD.

Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. […]

Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy […]

Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that targets the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA) and the CD3 antigen on T lymphocytes. It demonstrates significant antitumor activity and high efficacy in patients with late-stage relapsed/refractory multiple myeloma (RRMM). MW: 145.78 KD.

Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.

Gefurulimab is a humanized bispecific VHH antibody targeting both terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory effects. It inhibits the terminal complement pathway by blocking the cleavage of C5 into C5a and C5b, reducing complement-mediated inflammation and cell lysis. By binding to albumin, gefurulimab increases its half-life, offering a potent and […]

Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: […]

Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 […]

TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing […]